News-Blog EN - CANTREAT

Truck

Targeted Information, Honest Support – The CANTREAT Blog

Cancer changes lives—and we are transforming cancer therapy.
Our blog offers current insights into the world of CANTREAT: from medical background and research findings to personal stories and new developments in oncology. Clear, accessible, and always with one goal: to provide hope – and open up new perspectives.

BIO-Europe, Messe Wien

BIO-Europe Vienna: Successful Partnering for CANTREAT – and a Clear Signal for Our Mission

18. November 2025

Successful partnering for CANTREAT at BIO-Europe in Vienna: Productive 1:1 meetings, concrete follow-ups with development partners, and strategic investor discussions on financing, scaling, and study planning.

The financial potential of CANTREAT

18. June 2025

According to the European Cancer Information System (ECIS), there were 2.68 million new cancer cases in the EU in 2020 (Austria: 44,294, Germany: 538,140).

Cancer – Numbers and facts

18. June 2025

Cancer is one of the most frightening diagnoses today and the numbers continue to rise!

CANTREAT – Medical device or pharmaceutical?

18. May 2024

CANTREAT is classified as a medical device: it does not act pharmacologically but serves as a precise distribution method that receives physician-defined pharmaceuticals, transports them to the targeted site, and retains them there.

Chemotherapy – The status today

10. March 2024

CANTREAT enables a locally targeted, significantly lower-dose chemotherapy that spares healthy cells, reduces side effects, and thereby improves the immune system, vital functions, and chances of recovery. CANTREAT enables a locally targeted, significantly lower-dose chemotherapy that spares healthy cells, reduces side effects, and thereby improves the immune system, vital functions, and chances of recovery.

The USP of the CANTREAT-Method

10. December 2023

CANTREAT consolidates proven approaches from globally researched drug targeting and, with patent-pending components, new materials, and innovative techniques, delivers an efficient, low-side-effect, locally targeted therapy without costly apparatus—a medical novelty with revolutionary potential.

Tyrolean State Prize for Science awarded to Prof. Dr. Andreas Bernkop-Schnürch

8. November 2023

Every year, the province of Tyrol honors a personality from three alternating disciplines who has made outstanding achievements in the field of research and science.

Beitrag in der Tiroler Tageszeitung vom 16.08.2023

Reward for our specialist

16. August 2023

Article in the Tiroler Tageszeitung of August 16th, 2023

Cooperation with the MED-UNI in Innsbruck is working

8. March 2023

Together with the Institute of Pharmacy at the Leopold-Franzens University of Innsbruck, the basis for the two most essential research topics considered as USP is being developed in a project funded by the Province of Tyrol.

BIO-Europe Vienna: Successful Partnering for CANTREAT – and a Clear Signal for Our Mission

The financial potential of CANTREAT

Cancer – Numbers and facts

CANTREAT – Medical device or pharmaceutical?

Chemotherapy – The status today

The USP of the CANTREAT-Method

Tyrolean State Prize for Science awarded to Prof. Dr. Andreas Bernkop-Schnürch

Reward for our specialist

Cooperation with the MED-UNI in Innsbruck is working

Address

Contact

Legal matters

Social Networks